Guardant Health, Inc.GHNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
2.87%
↓ 69% below average
Average (34q)
9.14%
Historical baseline
Range
High:43.06%
Low:-12.62%
Volatility
609.3%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 2.87% |
| Q2 2025 | -1.21% |
| Q1 2025 | -5.37% |
| Q4 2024 | 7.14% |
| Q3 2024 | 5.06% |
| Q2 2024 | -0.84% |
| Q1 2024 | -6.74% |
| Q4 2023 | -4.26% |
| Q3 2023 | 3.86% |
| Q2 2023 | -2.97% |
| Q1 2023 | -12.62% |
| Q4 2022 | 6.56% |
| Q3 2022 | 17.04% |
| Q2 2022 | 4.52% |
| Q1 2022 | 11.96% |
| Q4 2021 | 2.89% |
| Q3 2021 | 11.37% |
| Q2 2021 | 14.80% |
| Q1 2021 | 37.80% |
| Q4 2020 | 11.14% |
| Q3 2020 | -0.20% |
| Q2 2020 | -1.88% |
| Q1 2020 | 43.06% |
| Q4 2019 | 5.32% |
| Q3 2019 | 25.79% |
| Q2 2019 | 19.71% |
| Q1 2019 | -2.02% |
| Q4 2018 | 16.83% |
| Q3 2018 | 23.36% |
| Q2 2018 | 39.96% |
| Q1 2018 | 1.66% |
| Q4 2017 | 12.06% |
| Q3 2017 | 21.27% |
| Q2 2017 | 11.89% |
| Q1 2017 | 0.00% |